Methods: We evaluated the role of CD38 as a determinant of tumor immune microenvironment in SCLC with bulk and single-cell transcriptomic analyses and protein assessments of clinical samples and ...

After years off medication, I finally enjoyed a grapefruit cocktail — symbolizing freedom from cancer’s constant shadow and hope for the future.

NEW YORK – A2 Biotherapeutics has treated the first solid tumor patient with its CAR T-cell therapy A2B395 in a Phase I/II clinical trial, the firm announced Thursday. Agoura Hills, California-based ...